Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The DBA program is a therapeutic development initiative focused on Diamond-Blackfan Anemia (DBA), a rare genetic bone marrow failure syndrome. The program is a collaboration between Fulcrum Therapeutics and CAMP4 Therapeutics, leveraging CAMP4's proprietary GeneCircuit platform to identify regulatory RNAs (regRNAs) that control the expression of ribosomal protein genes. DBA is primarily caused by haploinsufficiency of genes encoding ribosomal proteins, most commonly RPS19, RPL5, and RPL11, which leads to impaired ribosome biogenesis and erythroid progenitor apoptosis. The program aims to discover and develop small molecule therapies that can upregulate the expression of the remaining functional allele of the affected ribosomal protein gene, thereby restoring normal red blood cell production (erythropoiesis).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DBA program.